A multicenter retrospective analysis, which included 275 MM patients, revealed dismal outcomes, particularly in penta-refractory patients (i.e., refractory to two proteasome inhibitors, 2 immunomodulatory agents, and 1 anti-CD38 monoclonal antibody, n=70), where the median overall survival (OS) was about 6 months (4). The gene discussed is CD38; the disease is Miyoshi myopathy.